K
Klara Totpal
Researcher at Genentech
Publications - 70
Citations - 8919
Klara Totpal is an academic researcher from Genentech. The author has contributed to research in topics: Receptor & Tumor necrosis factor alpha. The author has an hindex of 38, co-authored 68 publications receiving 8103 citations. Previous affiliations of Klara Totpal include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
David A. Lawrence,Zahra Shahrokh,Scot A. Marsters,Kirsten Achilles,Danny Shih,Barbara Mounho,Kenneth J. Hillan,Klara Totpal,Laura DeForge,Peter Schow,Jeffrey Hooley,Steve Sherwood,Roger Pai,Susan Leung,Lolo Khan,Brian Gliniak,Jeanine L. Bussiere,Craig A. Smith,Stephen S. Strom,Sean K. Kelley,Judith A. Fox,Deborah Thomas,Avi Ashkenazi +22 more
TL;DR: These findings not only provide a novel insight into the pathogenesis of the transplant-related atherosclerosis, but also point to a new therapeutic strategy that involves targeting of homing, differentiation and proliferation of putative smooth-muscle progenitor cells derived from the recipient.
Journal ArticleDOI
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Esohe Ekinaduese Idusogie,L.G. Presta,H. Gazzano-Santoro,Klara Totpal,Pin Yee Wong,Mark Ultsch,Y.G. Meng,Michael G. Mulkerrin +7 more
TL;DR: The results demonstrate that the previously described C1q binding motif in murine IgG2b constituting residues E318, K320, and K322 is not applicable to a human IgG1 when challenged with either human, rabbit, or guinea pig complement and suggest that there are species-specific differences in the C 1q binding site of Igs.
Journal ArticleDOI
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner,Elizabeth Punnoose,Thomas Januario,David A. Lawrence,Robert M. Pitti,Kate Lancaster,Dori Lee,Melissa von Goetz,Sharon Yee,Klara Totpal,Ling Huw,Viswanatham Katta,Guy Cavet,Sarah G. Hymowitz,Lukas C. Amler,Avi Ashkenazi +15 more
TL;DR: A new link between death-receptor O-glycosylation and apoptotic signaling is uncovered, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.
Journal ArticleDOI
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
Heidi LeBlanc,David A. Lawrence,Eugene Varfolomeev,Klara Totpal,John Morlan,Peter Schow,Sharon Fong,Ralph H. Schwall,Dominick Sinicropi,Avi Ashkenazi +9 more
TL;DR: It is shown that Bax mutation in mismatch repair–deficient tumors can cause resistance to death receptor–targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.
Journal ArticleDOI
Engineered Antibodies with Increased Activity to Recruit Complement
Esohe Ekinaduese Idusogie,Pin Yee Wong,Leonard G. Presta,Helene Gazzano-Santoro,Klara Totpal,Mark Ultsch,Michael G. Mulkerrin +6 more
TL;DR: It is revealed that the residues K326 and E333 play a significant role in the control of the biological activity of an IgG molecule and can rescue the activity of a inactive IgG isotype.